Carine Dufau

Centre National de la Recherche Scientifique — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

5h-index280citations23works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sphingolipid Metabolism and Signaling(13), Cancer Immunotherapy and Biomarkers(9), CAR-T cell therapy research(6), Immunotherapy and Immune Responses(4), Nanoplatforms for cancer theranostics(4)

Publications23 total

<scp>TNF</scp> signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the <scp>MELANFα</scp> clinical study
International Journal of Cancer·2025· 1 citedOpen Access
Targeting ceramide metabolism in melanoma to improve the efficacy of immune checkpoint inhibitor therapy: from basic mechanisms to the clinic.
SPIRE - Sciences Po Institutional REpository·2024
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients
Frontiers in Immunology·2024· 3 citedOpen Access
A fluorogenic substrate for the detection of lipid amidases in intact cells
Journal of Lipid Research·2024· 1 citedOpen Access
Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation: from basic research to immunotherapy in advanced melanoma patients.
SPIRE - Sciences Po Institutional REpository·2023
Supplementary Data File S1 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Data from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Data File S1 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Tables and Figures from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Data File S2 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Data File S2 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Data from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Tables and Figures from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Data from Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
2023Open Access
Supplementary Data from Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
2023Open Access
Data from Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
2023Open Access
Supplementary Data from Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
2023Open Access
Role of the ceramide metabolism in TNF-induced melanoma dedifferentiation
2022Open Access
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Cancer Immunology Research·2021· 51 citedOpen Access
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
Clinical Cancer Research·2020· 97 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Nathalie Andrieu‐Abadie(22), Bruno Ségui(22), Anne Montfort(20), Thierry Levade(20), Céline Colacios(17), Thomas Filleron(16), Jean Milhès(15), Marie Tosolini(11), Christopher J. Clarke(11), Virginie Garcia(11), Nicolás Meyer(10), Joëlle Riond(10), Florie Bertrand(9), Julia Rochotte(9), Julia Gilhodes(9), Caroline Imbert(9), Florent Dufour(9), Andrei Constantinescu(9), Nilton De França(9), Michel Record(9)